10 results on '"Cecchin, Diego"'
Search Results
2. (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
- Author
-
Tiepolt, Solveig, Becker, Georg-Alexander, Wilke, Stephan, Cecchin, Diego, Rullmann, Michael, Meyer, Philipp M., Barthel, Henryk, Hesse, Swen, Patt, Marianne, Luthardt, Julia, Wagenknecht, Gudrun, Sattler, Bernhard, Deuther-Conrad, Winnie, Ludwig, Friedrich-Alexander, Fischer, Steffen, Gertz, Hermann-Josef, Smits, René, Hoepping, Alexander, Steinbach, Jörg, Brust, Peter, and Sabri, Osama
- Published
- 2021
- Full Text
- View/download PDF
3. [18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases.
- Author
-
Evangelista, Laura, Crimì, Filippo, Visentin, Andrea, Voltan, Giacomo, Trentin, Livio, Lacognata, Carmelo, Cecchin, Diego, and Ceccato, Filippo
- Subjects
LYMPHOMAS ,ADRENAL gland cancer ,COMPUTED tomography ,MAGNETIC resonance imaging ,METASTASIS - Abstract
Aim. The present study aimed to assess the existing data about Primary Adrenal Lymphoma (PAL) evaluated with FDG PET and to describe a small monocentric series of cases. A systematic analysis (from 2010 to 2022) was made by using PubMed and Web of Science databases reporting data about the role of FDG PET/CT in patients with suspicious or known adrenal lymphoma. The quality of the papers was assessed by using QUADAS-2 criteria. Moreover, from a single institutional collection between 2010 and 2021, data from patients affected by adrenal lymphoma and undergoing contrast-enhanced compute tomography (ceCT)/magnetic resonance (MR) and FDG PET/CT or PET/MR were retrieved and singularly described. Seventy-eight papers were available from PubMed and 25 from Web of Science. Forty-seven (Nr. 47) Patients were studied, most of them in the initial staging of disease (n = 42; 90%). Only in one paper, the scan was made before and after therapy. The selected clinical cases were relative to the initial staging of disease, the restaging, and the evaluation of response to therapy. PET/CT and PET/MR always showed a high FDG uptake in the primary adrenal lesions and in metastatic sites. Moreover, PET metrics, such as maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV), were elevated in all primary adrenal lesions. In conclusions, FDG PET either coupled with CT or MRI can be useful in staging, restaging, and for the evaluation of treatment response in patients affected by PAL [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Quantification of Brain β-Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study.
- Author
-
Garon, Michela, Weis, Luca, Fiorenzato, Eleonora, Pistonesi, Francesca, Cagnin, Annachiara, Bertoldo, Alessandra, Anglani, Mariagiulia, Cecchin, Diego, Antonini, Angelo, and Biundo, Roberta
- Subjects
MILD cognitive impairment ,PARKINSON'S disease ,CEREBRAL amyloid angiopathy ,SYMPTOMS ,EXECUTIVE function ,MANN Whitney U Test - Abstract
Background: Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with faster cognitive decline and conversion to dementia. There is uncertainty about the role of β-amyloid (Aβ) co-pathology and its contribution to the variability in PD-MCI profile and cognitive progression. Objective: To study how presence of Aβ affects clinical and cognitive manifestations as well as regional brain volumes in PD-MCI. Methods: Twenty-five PD-MCI patients underwent simultaneous PET/3T-MRI with [
18 F]flutemetamol and a clinical and neuropsychological examination allowing level II diagnosis. We tested pairwise differences in motor, clinical, and cognitive features with Mann–Whitney U test. We calculated [18 F]flutemetamol (FMM) standardized uptake value ratios (SUVR) in striatal and cortical ROIs, and we performed a univariate linear regression analysis between the affected cognitive domains and the mean SUVR. Finally, we investigated differences in cortical and subcortical brain regional volumes with magnetic resonance imaging (MRI). Results: There were 8 Aβ+ and 17 Aβ- PD-MCI. They did not differ for age, disease duration, clinical, motor, behavioral, and global cognition scores. PD-MCI-Aβ+ showed worse performance in the overall executive domain (p = 0.037). Subcortical ROIs analysis showed significant Aβ deposition in PD-MCI-Aβ+ patients in the right caudal and rostral middle frontal cortex, in precuneus, in left paracentral and pars triangularis (p < 0.0001), and bilaterally in the putamen (p = 0.038). Cortical regions with higher amyloid load correlated with worse executive performances (p < 0.05). Voxel-based morphometry (VBM) analyses showed no between groups differences. Conclusions: Presence of cerebral Aβ worsens executive functions, but not motor and global cognitive abilities in PD-MCI, and it is not associated with middle-temporal cortex atrophy. These findings, together with the observation of significant proportion of PD-MCI-Aβ-, suggest that Aβ may not be the main pathogenetic determinant of cognitive deterioration in PD-MCI, but it would rather aggravate deficits in domains vulnerable to Parkinson primary pathology. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3.
- Author
-
Guedj, Eric, Varrone, Andrea, Boellaard, Ronald, Albert, Nathalie L., Barthel, Henryk, van Berckel, Bart, Brendel, Matthias, Cecchin, Diego, Ekmekcioglu, Ozgul, Garibotto, Valentina, Lammertsma, Adriaan A., Law, Ian, Peñuelas, Iván, Semah, Franck, Traub-Weidinger, Tatjana, van de Giessen, Elsmarieke, Van Weehaeghe, Donatienne, and Morbelli, Silvia
- Subjects
BRAIN imaging ,CLINICAL indications ,NUCLEAR medicine ,NEURODEGENERATION ,HYPERGLYCEMIA ,GLUCOSE metabolism ,LYMPHOMA diagnosis ,DIAGNOSIS of dementia ,DIAGNOSIS of epilepsy ,ENCEPHALITIS diagnosis ,BRAIN ,MOVEMENT disorders ,MENTAL health ,GLIOMAS ,POSITRON emission tomography ,RADIOPHARMACEUTICALS ,PROFESSIONAL associations ,DEOXY sugars ,ONCOLOGY - Abstract
The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [
18 F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18 F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18 F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Imaging Studies in Cushing’s Syndrome
- Author
-
Lumachi, Franco, Zucchetta, P, Cecchin, Diego, and Motta, Raffaella
- Subjects
adrenal glands hyperfunction ,adrenal glands ,hypertension ,Cushing disease ,Cushing's syndrome ,cortisol ,PET ,Cushing ,adrenal tumors ,adrenal CT ,adrenal scintigraphy ,Cushing disease, Cushing syndrome, adrenal glands, adrenal scintigraphy, adrenal CT, PET, MRI, adrenal tumors, adrenal masses, hypertension ,Cushing syndrome ,adrenal masses ,scintigraphy ,Cushing, Cushing's syndrome, adrenal glands, adrenal glands hyperfunction, cortisol, CT, MRI, hypertension, scintigraphy, adrenal tumors ,CT ,MRI - Published
- 2012
7. Molecular Imaging of Pulmonary Inflammation and Infection.
- Author
-
Giraudo, Chiara, Evangelista, Laura, Fraia, Anna Sara, Lupi, Amalia, Quaia, Emilio, Cecchin, Diego, and Casali, Massimiliano
- Subjects
FLUORODEOXYGLUCOSE F18 ,LUNG infections ,BACTERIAL cell membranes ,LEUCOCYTES ,POSITRON emission tomography ,DRUG resistance in bacteria - Abstract
Infectious and inflammatory pulmonary diseases are a leading cause of morbidity and mortality worldwide. Although infrequently used in this setting, molecular imaging may significantly contribute to their diagnosis using techniques like single photon emission tomography (SPET), positron emission tomography (PET) with computed tomography (CT) or magnetic resonance imaging (MRI) with the support of specific or unspecific radiopharmaceutical agents.
18 F-Fluorodeoxyglucose (18 F-FDG), mostly applied in oncological imaging, can also detect cells actively involved in infectious and inflammatory conditions, even if with a low specificity. SPET with nonspecific (e.g.,67 Gallium-citrate (67 Ga citrate)) and specific tracers (e.g., white blood cells radiolabeled with111 Indium-oxine (111 In) or99m Technetium (99m Tc)) showed interesting results for many inflammatory lung diseases. However,67 Ga citrate is unfavorable by a radioprotection point of view while radiolabeled white blood cells scan implies complex laboratory settings and labeling procedures. Radiolabeled antibiotics (e.g., ciprofloxacin) have been recently tested, although they seem to be quite unspecific and cause antibiotic resistance. New radiolabeled agents like antimicrobic peptides, binding to bacterial cell membranes, seem very promising. Thus, the aim of this narrative review is to provide a comprehensive overview about techniques, including PET/MRI, and tracers that can guide the clinicians in the appropriate diagnostic pathway of infectious and inflammatory pulmonary diseases. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Data-driven analysis of regional brain metabolism in behavioral frontotemporal dementia and late-onset primary psychiatric diseases with frontal lobe syndrome: A PET/MRI study.
- Author
-
Cagnin, Annachiara, Pigato, Giorgio, Pettenuzzo, Ilaria, Zorzi, Giovanni, Roiter, Beatrice, Anglani, Maria Giulia, Bussè, Cinzia, Mozzetta, Stefano, Gabelli, Carlo, Campi, Cristina, and Cecchin, Diego
- Subjects
- *
FRONTAL lobe diseases , *MENTAL illness , *FRONTOTEMPORAL dementia , *FRONTOTEMPORAL lobar degeneration , *MOTOR neurons ,BRAIN metabolism - Abstract
Late-onset primary psychiatric disease (PPD) and behavioral frontotemporal dementia (bvFTD) present with a similar frontal lobe syndrome. We compare brain glucose metabolism in bvFTD and late-onset PPD and investigate the metabolic correlates of cognitive and behavioral disturbances through FDG-PET/MRI. We studied 37 bvFTD and 20 late-onset PPD with a mean clinical follow-up of three years. At baseline evaluation, metabolism of the dorsolateral, ventrolateral, orbitofrontal regions and caudate could classify the patients with a diagnostic accuracy of 91% (95% CI: 0.81–0.98%). 45% of PPD showed low-grade hypometabolism in the anterior cingulate and/or parietal regions. Frontal lobe metabolism was normal in 32% of genetic bvFTD and bvFTD with motor neuron signs. Hypometabolism of the frontal and caudate regions could help in distinguishing bvFTD from PPD, except in cases with motor neuron signs and/or genetic bvFTD for which brain metabolism may be less informative. • Frontal lobe syndrome is shared by late-onset primary psychiatric disease and bvFTD. • Brain glucose metabolism may be mostly useful in the differential diagnosis. • Frontal cortex/caudate metabolism guided a correct classification in 91% of cases. • Sparing of frontal metabolism may be present in bvFTD with MND or genetic bvFTD. • Hypometabolism of parietal cortex may be present in psychiatric diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
- Author
-
Evangelista, Laura, Ravelli, Ilaria, Bignotto, Antonio, Cecchin, Diego, and Zucchetta, Pietro
- Subjects
- *
NEUROENDOCRINE tumors , *PEPTIDE receptors , *POSITRON emission tomography computed tomography , *MAGNETIC resonance imaging , *LUNG cancer , *PATIENT selection - Abstract
The aim of the present review was to assess the role of combined 18F-Fluorodeoxyglucose (F-18 FDG) and Ga-68 DOTA-peptides positron emission tomography (PET)-computed tomography (CT) in neuroendocrine tumors (NETs). We have searched MEDLINE databases, including PubMed and Scopus, for studies about the combined FDG and Ga-68 DOTA-peptides PET-CT or PET/Magnetic Resonance Imaging (MRI) in NETs in the last 15 years (from 2004 to November 2019). No limits were applied to the search strategy. Abstracts, reviews, letters to editors, and editorials were excluded. Seven studies met the inclusion criteria. In total 236 patients received both 68Ga-DOTA-peptides and F-18 FDG PET-CT for the characterization of NETs. In particular, 84 patients had a neuroendocrine lung tumor while the others mainly a gastroenteropancreatic NET. The combined use of F-18 FDG and Ga-68 DOTA-peptides (mainly TOC) PET studies provides complementary information regarding different biological characteristics of the lesions, thus enabling a more accurate selection of patients for targeted radionuclide therapy and a better stratification of the prognosis. Ga-68 DOTA-peptides and F-18 FDG PET should be considered complementary in patients with NETs. They should be both performed in the initial staging and during follow-up, with a specific selection of patients and in a multidisciplinary vision. • Ga-68 DOTA-peptides and F-18 FDG PET-CT should be both performed in patients with neuroendocrine tumors. • Ga-68 DOTA-peptides uptake is higher in low-grade NETs, while F-18 FDG PET-CT uptake is high in G2 and G3 NETs. • F-18 FDG should be performed in case of negative or slightly positive Ga-68 DOTA-peptides PET-CT for identification of dedifferentiation status. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. 10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients
- Author
-
Fabrizio Dal Moro, Laura Evangelista, Ilaria Ravelli, Franca Chierichetti, Tania Baresic, Tommaso Vincenzo Bartolotta, Pierpaolo Alongi, Eugenio Borsatti, Giuseppe Trifirò, Marco Rensi, I Rambaldi, Mirco Bartolomei, Manuel Tredici, Diego Cecchin, Fabio Zattoni, Elisabetta Brugola, Davide Donner, Orazio Schillaci, Agostino Chiaravalloti, Mohsen Farsad, Marta Burei, Decio Capobianco, Zattoni, Fabio, Ravelli, Ilaria, Rensi, Marco, Capobianco, Decio, Borsatti, Eugenio, Baresic, Tania, Chiaravalloti, Agostino, Schillaci, Orazio, Alongi, Pierpaolo, Bartolotta, Tommaso Vincenzo, Rambaldi, Ilaria, Bartolomei, Mirco, Farsad, Mohsen, Tredici, Manuel, Donner, Davide, Chierichetti, Franca, Trifirò, Giuseppe, Brugola, Elisabetta, Burei, Marta, Dal Moro, Fabrizio, Cecchin, Diego, and Evangelista, Laura
- Subjects
Biochemical recurrence ,Male ,medicine.medical_specialty ,Prostate biopsy ,recurrence ,PET/CT ,choline ,prostate cancer ,staging ,030218 nuclear medicine & medical imaging ,Choline ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Settore MED/36 ,Prostate ,Positron Emission Tomography Computed Tomography ,80 and over ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Tomography ,Cancer staging ,Aged ,Aged, 80 and over ,PET-CT ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,X-Ray Computed ,Prostate-specific antigen ,medicine.anatomical_structure ,PET ,030220 oncology & carcinogenesis ,Radiology ,Neoplasm Grading ,Radiopharmaceuticals ,business ,Settore MED/36 - Diagnostica Per Immagini E Radioterapia ,Tomography, X-Ray Computed ,CT - Abstract
Purpose The primary aim of this multicenter retrospective analysis is to examine the role of(18)F-choline PET/CT as a diagnostic tool for staging and restaging prostate cancer (PCa) in a large population in the light of 10 years of clinical experience. A secondary aim of the study is to produce data on the predictors of a positive(18)F-choline PET/CT result in the setting of PCa primaries and biochemical recurrences. Materials and Methods This multicenter retrospective cohort study is based on data collected by 9 Italian nuclear medicine departments. Between October 2008 and September 2019, 3343 men underwent(18)F-choline PET/CT scans before receiving definitive treatments for a primary PCa or biochemical recurrence. Inclusion criteria were (1) histologically proven PCa (on surgical specimens or prostate biopsies from patients not treated surgically) and (2) availability of clinical and pathological data, including serum prostate specific antigen (PSA) level at the time of PET/CT scanning. Results F-18-choline PET/CT was performed in 545 cases (16.4%) for cancer staging and in 2798 (83.6%) for restaging purposes, and the result was positive in 540 (99.1%) for the former and 1993 (71.2%) for the latter. A positive PET/CT result was always associated with a high Gleason score (>7) and high PSA levels (P< 0.01). The percentage of patients with a PSA threshold less than 1.0 ng/mL for performing PET/CT was higher in the years 2014 to 2019 (n = 341, 25% of cases) than during the previous period (n = 148, 16%; in 2008-2013). When used for staging purposes, receiver operating characteristic analysis showed that PSA levels of 9.2, 16.4, and 16.6 ng/mL were the optimal cutoffs for distinguishing between positive and negative PET/CT findings for local disease, lymph node involvement, and metastasis, respectively. In the restaging setting, a PSA level of 1.27 ng/mL was the optimal cutoff for distinguishing between a positive and negative PET/CT scan. Conclusions F-18-choline PET/CT can help identify early recurrences, even in the case of low PSA levels (
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.